#BEGIN_DRUGCARD DB00718

# AHFS_Codes:
08:18.32

# ATC_Codes:
J05AF08

# Absorption:
Approximate oral bioavailability is 59%.

# Biotransformation:
Following oral administration, adefovir dipivoxil is rapidly converted to adefovir. Forty-five percent of the dose is recovered as adefovir in the urine over 24 hours at steady state following 10 mg oral doses. Adefovir is not a substrate of the cytochrome P450 enzymes.

# Brand_Mixtures:
Not Available

# Brand_Names:
Hepsera
Preveon

# CAS_Registry_Number:
142340-99-6

# ChEBI_ID:
Not Available

# Chemical_Formula:
C20H32N5O8P

# Chemical_IUPAC_Name:
[({[2-(6-amino-9H-purin-9-yl)ethoxy]methyl}({[(2,2-dimethylpropanoyl)oxy]methoxy})phosphoryl)oxy]methyl 2,2-dimethylpropanoate

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment of hepatitis B. It is a failed treatment for HIV. [Wikipedia]

# Dosage_Forms:
Tablet	Oral

# Drug_Category:
Antiviral Agents
Reverse Transcriptase Inhibitors

# Drug_Interactions:
Valganciclovir	The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Adefovir Dipivoxil, may be enhanced by Valganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is recommended.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
0.8

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
19 mg/mL at pH 2.0 and 0.4 mg/mL at pH 7.2.

# Food_Interactions:
Take without regard to meals.

# GenBank_ID:
Not Available

# Generic_Name:
Adefovir Dipivoxil

# HET_ID:
Not Available

# Half_Life:
Terminal elimination half-life of 7.48 &plusmn; 1.65 hours

# InChI_Identifier:
InChI=1S/C20H32N5O8P/c1-19(2,3)17(26)30-11-32-34(28,33-12-31-18(27)20(4,5)6)13-29-8-7-25-10-24-14-15(21)22-9-23-16(14)25/h9-10H,7-8,11-13H2,1-6H3,(H2,21,22,23)

# InChI_Key:
InChIKey=WOZSCQDILHKSGG-UHFFFAOYSA-N

# Indication:
For the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D01655

# LIMS_Drug_ID:
718

# Mechanism_Of_Action:
Adefovir dipivoxil is a prodrug of adefovir. Adefovir is an acyclic nucleotide analog of adenosine monophosphate which is phosphorylated to the active metabolite adefovir diphosphate by cellular kinases. Adefovir diphosphate inhibits HBV DNA polymerase (reverse transcriptase) by competing with the natural substrate deoxyadenosine triphosphate and by causing DNA chain termination after its incorporation into viral DNA. The inhibition constant (Ki) for adefovir diphosphate for HBV DNA polymerase was 0.1 &mu;M. Adefovir diphosphate is a weak inhibitor of human DNA polymerases &alpha; and &gamma; with Ki values of 1.18 &mu;M and 0.97&mu;M, respectively.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
501.4705

# Molecular_Weight_Mono:
501.198849537

# Organisms_Affected:
Hepatitis B virus

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Adefovir Dipivoxil Pathway	SMP00418

# PharmGKB_ID:
PA10005

# Pharmacology:
Adefovir dipivoxil a diester prodrug of adefovir. Adefovir is an acyclic nucleotide analog with activity against human hepatitis B virus (HBV). The concentration of adefovir that inhibited 50% of viral DNA synthesis (IC50) in vitro ranged from 0.2 to 2.5 &mu;M in HBV transfected human hepatoma cell lines. The combination of adefovir with lamivudine showed additive anti-HBV activity.

# Predicted_LogP_Hydrophobicity:
1.49

# Predicted_LogS:
-2.9

# Predicted_Water_Solubility:
6.33e-01 g/l

# Primary_Accession_No:
DB00718

# Protein_Binding:
&le;4% over the adefovir concentration range of 0.1 to 25 &mu;g/mL

# PubChem_Compound_ID:
60871

# PubChem_Substance_ID:
46507520

# RxList_Link:
http://www.rxlist.com/cgi/generic3/hepsera.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00781

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
ADV
Adefovir
Adefovir pivoxil
Adefovirdipivoxl
GS-840
PMEA
bis-POM PMEA

# Synthesis_Reference:
Not Available

# Toxicity:
Renal tubular nephropathy characterized by histological alterations and/or increases in BUN and serum creatinine was the primary dose-limiting toxicity associated with administration of adefovir dipivoxil in animals. Nephrotoxicity was observed in animals at systemic exposures approximately 3&ndash;10 times higher than those in humans at the recommended therapeutic dose of 10 mg/day.

# Update_Date:
2013-02-08 16:19:35 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Adefovir

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
14647052	Kock J, Baumert TF, Delaney WE 4th, Blum HE, von Weizsacker F: Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary tupaia hepatocytes. Hepatology. 2003 Dec;38(6):1410-8.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
19187868	Chien RN, Liaw YF: Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. Best Pract Res Clin Gastroenterol. 2008;22(6):1081-92.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
M32138

# Drug_Target_1_GenBank_ID_Protein:
329670

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
P

# Drug_Target_1_Gene_Sequence:
>2499 bp
ATGCCCCTATCTTATCAACACTTCCGGAGACTACTGTTGTTAGACGACGAGGCAGGTCCC
CTAGAAGAAGAACTCCCTCGCCTCGCAGACGAAGGTCTCAATCGCCACGTCGCAGAAGAA
CTCAATCTCGGGAATCTCAATGTTAGTATTCCCTGGACTCATAAGGTGGGAAACTTTACG
GGGCTTTATTCTTCTACTGTTCCTGTCTTTAACCCTCATTGGAAAACACCCTCTTTTCCT
AATATACATTTACACCAAGACATTATCAAAAAATGTGAACAATTTGTAGGCCCACTCACA
GTCAATGAGAAAAGAAGACTGCAATTGATTATGCCTGCTAGGTTTTATCCAAAGGTTACC
AAATATTTGCCATTGGATAAGGGTATTAAACCTTATTATCCAGAACATCTAGTTAATCAT
TACTTCCAAACCAGACATTATTTACACACTCTATGGAAGGCGGGTGTATTATATAAGAGA
GAAACTACACATAGCGCCTCATTTTGTGGGTCACCATATTCCTGGGAACAAGAGCTACAG
CATGGGGCAGAATCTTTCCACCAGCAATCCTCTGGGATTCTTTCCCGACCACCAGTTGGA
TCCAGCCTTCAGAGCAAACACTGCAAATCCAGATTGGGACTTCAATCCCAACAAGGACTC
CTGGCCAGACGCCAACAAGGTAGGAGCTGGAGCATTCGGGCTGGGATTCACCCCACCGCA
CGGAGGCCTTTTGGGGTGGAGCCCTCAGGCTCAGGGCATACTACAAACCTTGCCAGCAAA
TCCGCCTCCTGCCTCCACCAATCGCCAGTCAGGAAGGCAACCTACCCCTCTGTCTCCACC
TTTGAGAAACACTCATCCTCAGGCCATGCAGTGGAACTCCACAACCTTCCACCAAACTCT
GCAAGATCCCAGAGTGAGAGGCCTGTATCTCCCTGCTGGTGGCTCCAGTTCAGGAACAGT
AAACCCTGTTCCGACTACTGTCTCTCCCATATCGTCAATCTTCTCGAGGATTGGGGACCC
TGCGCTGAACATGGAGAACATCACATCAGGATTCCTAGGACCCCTGCTCGTGTTACAGGC
GGGGTTTTTCTTGTTGACAAAAATCCTCACAATACCGAAGAGTCTAGACTCGTGGTGGAC
TTCTCTCAATTTTCTAGGGGGAACCACCGTGTGTCTTGGCCAAAATTCGCAGTCCCCAAC
CTCCAATCACTCACCAACCTCCTGTCCTCCAACTTGTCCTGGTTATCGCTGGATGTGTCT
GCGGCGTTTTATCATCTTCCTCTTCATCCTGCTGCTATGCCTCATCTTCTTGTTGGTTCT
TCTGGACTATCAAGGTATGTTGCCCGTTTGTCCTCTGATTCCAGGATCTTCAACCACCAG
CACGGGACCATGCAGAACCTGCACGACTCCTGCTCAAGGAACCTCTATGTATCCCTCCTG
TTGCTGTACCAAACCTTCGGACGGAAATTGCACCTGTATTCCCATCCCATCATCCTGGGC
TTTCGGAAAATTCCTATGGGAGTGGGCCTCAGCCCGTTTCTCCTGGCTCAGTTTACTAGT
GCCATTTGTTCAGTGGTTCGTAGGGCTTTCCCCCACTGTTTGGCTTTTAGTTATATGGAT
GATGTGGTATTGGGGGCCAAAACTGTTCACCATCTTGAGTCCCTTTTTACCGCTGTTACC
AATTTTCTTTTGTCTTTGGGTATACATCTAAACCCTAACAAAACAAAAAGATGGGGTTAC
TCTTTACATTTTATGGGCTATGTCATTGGATGTTATGGGTCTTTGCCACAAGATCACATC
ATACAGAAAATCAAAGAATGTTTTAGAAAACTTCCTGTTAACAGGCCTATTGATTGGAAA
GTCTGTCAACGTATTGTGGGTCTTTTGGGATTTGCTGCTCCTTTTACACAATGTGGTTAT
CCTGCTTTAATGCCCTTGTATGCATGTATTCAATCTAAGCAGGCTTTCACTTTCTCGCCA
ACTTACAAGGCCTTTCTGTGTAAACAATACCTGAACCTTTACCCCGTTGCCCGGCAACGC
CCAGGTCTGTGCCAAGTGTTTGCTGACGCAACCCCCACTGGCTGGGGCTTGGTCATGGGC
CATCAGCGCATGCGTGGAACCTTTCAGGCTCCTCTGCCGATCCATACTGCGGAACTCCTA
GCCGCTTGTTTTGCTCGCAGCCGGTCTGGAGCAAACATTCTCGGGACGGATAACTCTGTT
GTTCTCTCCCGCAAATATACGTCGTTTCCATGGCTGCTAGGCTGTGCTGCCAACTGGATC
CTGCGCGGGACGTCCTTTGTTTACGTCCCGTCGGCGCTGAATCCCGCGGACGACCCTTCT
CGGGGCCGCTTGGGACTCTCTCGTCCCCTTCTCCGTCTGCCGTTTCGACCGACCACGGGG
CGCACCTCTCTTTACGCGGACTCCCCGTCTGTGCCTTCTCATCTGCCGGACCGTGTGCAC
TTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGA

# Drug_Target_1_General_Function:
Involved in RNA binding

# Drug_Target_1_General_References:
2345966	Tong SP, Li JS, Vitvitski L, Trepo C: Active hepatitis B virus replication in the presence of anti-HBe is associated with viral variants containing an inactive pre-C region. Virology. 1990 Jun;176(2):596-603.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
342

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
93591

# Drug_Target_1_Name:
P protein [Includes: DNA-directed DNA polymerase

# Drug_Target_1_Number_of_Residues:
832

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00078	RVT_1
PF00242	DNA_pol_viral_N
PF00336	DNA_pol_viral_C

# Drug_Target_1_Protein_Sequence:
>P protein [Includes: DNA-directed DNA polymerase
MPLSYQHFRRLLLLDDEAGPLEEELPRLADEGLNRHVAEELNLGNLNVSIPWTHKVGNFT
GLYSSTVPVFNPHWKTPSFPNIHLHQDIIKKCEQFVGPLTVNEKRRLQLIMPARFYPKVT
KYLPLDKGIKPYYPEHLVNHYFQTRHYLHTLWKAGVLYKRETTHSASFCGSPYSWEQELQ
HGAESFHQQSSGILSRPPVGSSLQSKHCKSRLGLQSQQGLLARRQQGRSWSIRAGIHPTA
RRPFGVEPSGSGHTTNLASKSASCLHQSPVRKATYPSVSTFEKHSSSGHAVELHNLPPNS
ARSQSERPVSPCWWLQFRNSKPCSDYCLSHIVNLLEDWGPCAEHGEHHIRIPRTPARVTG
GVFLVDKNPHNTEESRLVVDFSQFSRGNHRVSWPKFAVPNLQSLTNLLSSNLSWLSLDVS
AAFYHLPLHPAAMPHLLVGSSGLSRYVARLSSDSRIFNHQHGTMQNLHDSCSRNLYVSLL
LLYQTFGRKLHLYSHPIILGFRKIPMGVGLSPFLLAQFTSAICSVVRRAFPHCLAFSYMD
DVVLGAKTVHHLESLFTAVTNFLLSLGIHLNPNKTKRWGYSLHFMGYVIGCYGSLPQDHI
IQKIKECFRKLPVNRPIDWKVCQRIVGLLGFAAPFTQCGYPALMPLYACIQSKQAFTFSP
TYKAFLCKQYLNLYPVARQRPGLCQVFADATPTGWGLVMGHQRMRGTFQAPLPIHTAELL
AACFARSRSGANILGTDNSVVLSRKYTSFPWLLGCAANWILRGTSFVYVPSALNPADDPS
RGRLGLSRPLLRLPFRPTTGRTSLYADSPSVPSHLPDRVHFASPLHVAWRPP

# Drug_Target_1_Reaction:
deoxynucleoside triphosphate + DNAn = diphosphate + DNAn+1

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
P24024

# Drug_Target_1_SwissProt_Name:
DPOL_HBVD2

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
10.05

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB00718
